On March 14, 2023 Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported that new data will be presented demonstrating the promise of its SORT1+ Technology platform of proprietary peptides, and of its lead investigational peptide drug conjugate (PDC) candidate, sudocetaxel zendusortide (TH1902), in enabling targeted delivery of anticancer therapy (Press release, Theratechnologies, MAR 14, 2023, View Source [SID1234628665]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The new data, to be presented in three poster sessions at the 2023 annual meeting of the American Association for Cancer Research (AACR) (Free AACR Whitepaper) being held April 14-19 in Orlando, Fla., highlight a synergistic effect of sudocetaxel zendusortide in combination with programmed death-ligand 1 (PD-L1), checkpoint inhibitor therapy in a melanoma mouse model; high expression of the sortilin (SORT1) receptor in multiple tumor types compared to healthy tissues; and the rationale for using sudocetaxel zendusortide as a potential therapeutic approach in SORT1-positive triple-negative breast cancer (TNBC) and HER2-positive breast cancers.
"We are particularly encouraged by the potential synergistic activity of sudocetaxel zendusortide when combined with an anti-PD-L1 checkpoint inhibitor in a melanoma model," said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer of Theratechnologies. "Our new data continue to support the clinical development of sudocetaxel zendusortide as a single agent and in combination with other anticancer therapies. Together, the AACR (Free AACR Whitepaper) poster presentations provide fresh insights to guide our oncology program, and our efforts to bring advanced personalized therapies to patients with cancer."
Theratechnologies will present the following data on Tuesday April 18, 2023, from 9:00am-12:30pm Eastern Time (ET) at AACR (Free AACR Whitepaper) 2023:
Title: The peptide-drug conjugate sudocetaxel zendusortide (TH1902) potentiates anti-tumoral activity of the anti-PD-L1 checkpoint inhibitor and induces immune cell infiltration in a B16-F10 syngeneic melanoma model
Presenting Author: Michel Demeule, Ph.D., Theratechnologies
Session Category: Clinical Research Excluding Trials
Session Title: Molecular Targeted Therapies 2
Location: Poster Section 42
Poster Board Number: 24
Abstract Presentation Number: 4499
Title: Sudocetaxel zendusortide (TH1902), a peptide-drug conjugate for the treatment of sortilin-positive (SORT1+) TNBC and Her2-positive breast cancers
Presenting Author: Cyndia Charfi, Ph.D., Theratechnologies
Session Category: Clinical Research Excluding Trials
Session Title: Molecular Targeted Therapies 2
Location: Poster Section 42
Poster Board Number: 18
Abstract Presentation Number: 4493
Title: Differential expression of a novel transport receptor, SORT1 (sortilin), in cancer versus healthy tissues that can be utilized for targeted delivery of anti-cancer drugs
Presenting Author: Guylaine Roy, Ph.D., Theratechnologies
Session Category: Experimental and Molecular Therapeutics
Session Title: Identification of Molecular Targets 1
Location: Poster Section 17
Poster Board Number: 30
Abstract Presentation Number: 3942
About SORT1+ Technology and Sudocetaxel Zendusortide (TH1902)
Theratechnologies is currently developing a platform of proprietary peptides called SORT1+ TechnologyTM for cancer drug development targeting SORT1 receptors. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an attractive target for cancer drug development. Expression of SORT1 is associated with aggressive disease, poor prognosis and decreased survival. It is estimated that the SORT1 receptor is expressed in 40% to 90% of cases of endometrial, ovarian, colorectal, triple-negative breast and pancreatic cancers.
Sudocetaxel zendusortide (TH1902) is currently Theratechnologies’ lead investigational peptide drug conjugate candidate for the treatment of cancer derived from its SORT1+ Technology. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. The FDA granted fast track designation to TH1902 as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy. TH1902 is currently being evaluated in a Phase 1 clinical trial, although patient recruitment was voluntarily paused on December 1, 2022. In alignment with this decision, the FDA placed the trial on partial clinical hold and the Company is currently preparing responses to their questions and planning a protocol amendment.